NCT06627205 Sleep Restriction Therapy (SRT) for Sleep Problems in Children With Autism
| NCT ID | NCT06627205 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Autism Spectrum Disorder (ASD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2025-02-11 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 25 participants in total. It began in 2025-02-11 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this open label trial is to examine the acceptability, tolerability, and feasibility and preliminary effectiveness of sleep restriction therapy for sleep problems in children with autism spectrum disorder (ASD). Treatment will be delivered via secure telemedicine platform and consist of parent-training in delivering the intervention.
Eligibility Criteria
Inclusion Criteria: * diagnosed with autism spectrum disorder (based on history, review of available medical records including diagnostic testing, e.g., Autism Diagnostic Observation Schedule and/or Autism Diagnostic Interview-Revised, Childhood Autism Rating Scale-2) * with sleep disturbances (based on clinical interview, and Sleep Disturbance Scale for Children score \> 38) * stable pre-existing medication plans for at least 2 weeks * no planned changes in psychosocial and biomedical interventions during the intervention * an English-speaking parent able to consistently participate in study procedures * reside in California, USA Exclusion Criteria: * parent or child diagnosed with severe psychiatric disorder or unstable medical problem * children with active seizures or epilepsy * primary sleep disorder is a circadian rhythm sleep-wake disorder, as determined by the sleep interview and Children's ChronoType Questionnaire. * current active trial of sleep restriction therapy or history of an adequate trial of sleep restriction therapy.
Contact & Investigator
Emma K Baker, MPsych(Clin), PhD
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT06627205 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 12 Years, studying Autism Spectrum Disorder (ASD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06627205 currently recruiting?
Yes, NCT06627205 is actively recruiting participants. Contact the research team at ekbaker@stanford.edu for enrollment information.
Where is the NCT06627205 trial being conducted?
This trial is being conducted at Stanford, United States.
Who is sponsoring the NCT06627205 clinical trial?
NCT06627205 is sponsored by Stanford University. The principal investigator is Emma K Baker, MPsych(Clin), PhD at Stanford University. The trial plans to enroll 25 participants.